Accumulated promoter methylation as a potential biomarker for esophageal cancer.

Content Provider	Europe PMC
Author	Peng, Xianzhen Xue, Hengchuan Lü, Lingshuang Shi, Peiyi Wang, Jianping Wang, Jianming
Copyright Year	2017
Abstract	We performed a two-stage molecular epidemiological study to explore DNA methylation profiles for potential biomarkers of esophageal squamous cell carcinoma (ESCC) in a Chinese population. Infinium Methylation 450K BeadChip was used to identify genes with differentially methylated CpG sites. Sixteen candidate genes were validated by sequencing 1160 CpG sites in their promoter regions using the Illumina MiSeq platform. When excluding sites with negative changes, 10 genes (BNIP3, BRCA1, CCND1, CDKN2A, HTATIP2, ITGAV, NFKB1, PIK3R1, PRDM16 and PTX3) showed significantly different methylation levels among cancer lesions, remote normal-appearing tissues, and healthy controls. PRDM16 had the highest diagnostic value with the AUC (95% CI) of 0.988 (0.965–1.000), followed by PIK3R1, with the AUC (95% CI) of 0.969 (0.928–1.000). In addition, the methylation status was higher in patients with advanced cancer stages. These results indicate that aberrant DNA methylation may be a potential biomarker for the diagnosis of ESCC.
Journal	Oncotarget
Volume Number	8
PubMed Central reference number	PMC5352188
Issue Number	1
PubMed reference number	27893424
e-ISSN	19492553
DOI	10.18632/oncotarget.13510
Language	English
Publisher	Impact Journals LLC
Publisher Date	2017-01-01
Access Restriction	Open
Rights License	This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright: © 2017 Peng et al.
Subject Keyword	esophageal cancer epigenetics methylation next-generation sequencing diagnosis
Content Type	Text
Resource Type	Article
Subject	Oncology